GLP1R and Insulin resistance: For example, pioglitazone can improve liver steatosis, insulin resistance, and liver enzyme levels, but weight gain of about 3 to 5 kg is the most common adverse reaction,[4] and patients with obvious heart failure also It should not be taken, and it is also related to bladder cancer and bone loss after menopause.[5–8] Human glucagon-like peptide-1 (GLP-1) analogs, such as liraglutide, can suppress appetite, delay gastric emptying, and reduce weight.